Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy

Clinical data are being used to build a mathematical model to describe the clinical results of radiotherapy for prostate cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Sex eligibility

Male

Study type

Observational

Primary location

Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada

About this study

Clinical data (prostate-specific antigen [PSA] response after radiotherapy) are being used to build a mathematical model to describe the clinical results of radiotherapy for prostate cancer.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Prostate cancer treated with radiotherapy +/- hormones

Exclusion criteria

Prostatectomy

Sponsors and collaborators

Lead sponsor

AHS Cancer Control Alberta

Other

Collaborators

Cross Cancer Institute

Registry information

Important dates

Study start: 2004
Primary completion: 2008
Study completion: 2008
First posted: Aug 5, 2005
Registry last updated: Feb 24, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed